Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™

MOUNTAIN VIEW, Calif., March 17, 2026 /Digbi Newswire/ -- Digbi Health, the leader in precision biology for metabolic and digestive health, today announced a major expansion of its GLP-1 Compass™ platform with the launch of Digbi RxFund™.

This financial innovation provides employers and employees with streamlined, subsidized and cash-pay pathways for obesity care, ensuring high-quality clinical oversight outside of traditional, opaque pharmacy benefit designs.

The conventional PBM-based GLP-1 model forces employers into an "all-or-nothing" choice: absorb unsustainable financial risk or face employee dissatisfaction. Eli Lilly's direct-to-employer move validates that the market is shifting toward alternatives outside of traditional PBM models. Digbi RxFund™ gives employers a smarter path — combining flexible funding with precision metabolic care to ensure GLP-1 use is effective, appropriate, and sustainable.

— Ranjan Sinha, Founder and CEO, Digbi Health

Three flexible funding models

Recognizing that no two employer budgets are alike, the Digbi RxFund digital card platform allows employers to support GLP-1 access while maintaining predictable costs.

• Employer-defined contribution — Employers provide a fixed monthly subsidy toward the direct manufacturer cash price of GLP-1 medications, creating predictable costs and avoiding PBM pricing opacity.
• Employee cash-pay access — Employees can access the lowest available direct-to-manufacturer pricing, with integrated physician oversight and metabolic care support through Digbi.
• Traditional PBM integration — For employers maintaining GLP-1 coverage within their PBM formulary, Digbi provides clinical oversight and precision biology support alongside existing benefit design.

Beyond medication access

Unlike programs that focus only on medication access, Digbi's GLP-1 Compass platform supports the entire cardiometabolic and GI journey, helping employers manage costs while improving member health.

Personalized metabolic care helps overweight members improve outcomes before medications become necessary. Precision biology tools identify likely poor responders and improve medication outcomes. Precision nutrition manages GI side effects while proactively addressing hair loss and muscle mass depletion.

By addressing the underlying drivers of metabolic disease — including glucose response, gut health and genetics — Digbi helps members sustain results and avoid costly medication restart cycles.

Originally distributed via GLOBE NEWSWIRE.